NCT01870999View on ClinicalTrials.gov

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

aripiprazole IM depot

Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.

DRUG

aripiprazole tablets

Aripiprazole tablets 10 mg once daily in the morning for 14 days.

Trial Locations (7)

63118

Otsuka Investigative Site, St Louis

78756

Otsuka Investigative Site, Austin

90703

Otsuka Investigative Site, Cerritos

90723

Otsuka Investigative Site, Paramount

91206

Otsuka Investigative Site, Glendale

92845

Otsuka Investigative Site, Garden Grove

08046

Otsuka Investigative Site, Willingboro

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01870999 - A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot | Biotech Hunter | Biotech Hunter